Class 1. Drug-induced and Toxin-induced Pulmonary Hypertension

Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy

Layla Aref, Jacob J. Hughey, Sherwin Shirazi, Jennifer M. S. Sucre, Lisa BastaracheVanderbilt University Medical Center, Vanderbilt University School of Medicine and Vanderbilt University.United States Journal of the American Medical Association Network OpenJAMA Netw Open 2026; 9: DOI: 10.1001/jamanetworkopen.2026.22790 AbstractImportance: Evaluating the safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy is challenging due to ethical barriers […]

Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy Read More »

Inhalable extracellular vesicle delivered IL-10 mRNA attenuates pulmonary hypertension in rats

Guoliang Wang, Jie Liu, Peiyi Bai, Hong Jiao, Xiaohui Kong, Zhangke Guo, Gaopeng Li, Aijun LiuBeijing Children’s Hospital, Beijing Pediatric Research Institute, Capital Medical University and National Center for Children’s Health. Shanxi Bethune Hospital, Third Hospital of Shanxi Medical University, Shanxi Academy of Medical Sciences and Tongji Shanxi Hospital. General Hospital of Taiyuan Iron and

Inhalable extracellular vesicle delivered IL-10 mRNA attenuates pulmonary hypertension in rats Read More »

Non-invasive surrogate of main pulmonary artery stiffness is associated with right ventricular function in experimental pulmonary arterial hypertension

John D. Dauz, Bahram Mirani, J. Paul Santerre, Michelle P. Bendeck, Craig A. Simmons, Mark K. FriedbergHospital for Sick Children and University of Toronto. Ted Rogers Centre for Heart Research. Canada American Journal of Physiology Heart and Circulatory PhysiologyAm J Physiol Heart Circ Physiol 2026; DOI: 10.1152/ajpheart.00459.2026 AbstractMain pulmonary artery (MPA) stiffening increases right ventricular (RV)

Non-invasive surrogate of main pulmonary artery stiffness is associated with right ventricular function in experimental pulmonary arterial hypertension Read More »

Reversible Pulmonary Arterial Hypertension Due to Fenfluramine in a Young Child: A Case Report

Uzoma Ndukwe, Adrianne Parkey, Debopam Samanta, Abdelrahman Masri, Erin WillisUniversity of Arkansas for Medical Sciences.United States CureusCureus 2026; 18: DOI: 10.7759/cureus.108354 AbstractFenfluramine is approved for Dravet syndrome and Lennox-Gastaut syndrome (LGS) in children under two years of age and is increasingly used off-label for developmental and epileptic encephalopathies (DEEs). Due to the risk of pulmonary arterial

Reversible Pulmonary Arterial Hypertension Due to Fenfluramine in a Young Child: A Case Report Read More »

[Pulmonary Arterial Hypertension Impairs Duodenal Barrier Integrity in Rats]

Shouei Ishimaru, Satoshi Mizuno, Tomoya Tanada, Daisuke Saito, Keiichi Hirono, Keijiro Ibuki, Masato TaguchiUniversity of Toyama.Japan Yakugaku Zasshi (Journal of the Pharmaceutical Society of Japan)Yakugaku Zasshi 2026; DOI: 10.1248/yakushi.25-00165 AbstractPulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease that leads to right heart failure and systemic venous congestion. Such congestion can impair multiple organs, including

[Pulmonary Arterial Hypertension Impairs Duodenal Barrier Integrity in Rats] Read More »

Cx43 mediates nicotine-induced enhancement of mouse pulmonary arterial tone by downregulating Kv1.2 and Kv2.1 channels

Xiaomin Hou, Xuelu Jiang, Xin Meng, Jin Zhou, Di Xi, Xiaoxia Ren, Ming Gao, Yong’e Liu, Xiao Luo Yiwei Shi, Xiaojiang QinShanxi Medical University. China-Japan Friendship Hospital. Shanxi Coal Central Hospital. First hospital of Shanxi Medical University. China Food and Chemical ToxicologyFood Chem Toxicol 2026; DOI: 10.1016/j.fct.2026.116182 AbstractPulmonary hypertension (PH) is a chronic and complex condition

Cx43 mediates nicotine-induced enhancement of mouse pulmonary arterial tone by downregulating Kv1.2 and Kv2.1 channels Read More »

Amonafide Targeting NTSR1-PI3K/AKT/mTOR Signaling Attenuates Vascular Remodeling in Pulmonary Arterial Hypertension

Yong‐Jian Zhu, Jie‐Jian Kou, Ya‐Cong Bo, Meng‐Jie Zhang, Xin Fan, Lu‐Ling Zhao, Yi Yan, Hong Da Zhang, Wen‐Hui Wu, Ping Yuan, Yan Liu, Jun‐Zhuo Shi, Xiao‐Bin Pang, Yang‐Yang HeFirst Affiliated Hospital of Zhengzhou University. Huaihe Hospital and Henan University. Zhengzhou University. Shanghai Children’s Medical Center and Shanghai Jiao Tong University School of Medicine. Fuwai Hospital and Peking Union Medical College. Shanghai Pulmonary Hospital and School of Medicine Tongji University. China Journal of the American Heart AssociationJ Am Heart Assoc

Amonafide Targeting NTSR1-PI3K/AKT/mTOR Signaling Attenuates Vascular Remodeling in Pulmonary Arterial Hypertension Read More »

Efficacy and safety of fenfluramine in Dravet syndrome; A monocentric, observational study focused on initial dose, blood concentration, and reduction of concomitant medications

Akihiro Iguchi, Tokito Yamaguchi, Yu Tsuyusaki, Hideyuki Otani, Satoshi Mizutani, Mitsuhiro Miyashita, Manami Yabe, Katsumi ImaiNHO Shizuoka Institute of Epilepsy and Neurological Disorders and Asahi General Hospital. Japan Epilepsy and BehaviorEpilepsy Behav 2026; DOI: 10.1016/j.yebeh.2026.111070 AbstractObjective: To evaluate the optimal initial dose, efficacy, and adverse events of fenfluramine (FFA) in the treatment of intractable epilepsy in Dravet

Efficacy and safety of fenfluramine in Dravet syndrome; A monocentric, observational study focused on initial dose, blood concentration, and reduction of concomitant medications Read More »

Inflachromene attenuates monocrotaline-induced pulmonary arterial hypertension by suppressing the HMGB1-TLR4/RAGE-NF-κB signaling pathway

Yueru Wang, Dina Nuerlan, Bilali Paizula, Yimuran Kawulijiang, Jiyao Chen, Hong Zhu, Wentao Xiao, Zhayier Tueraili, Guoming ZhangFirst Affiliated Hospital of Xinjiang Medical University. Second Affiliated Hospital of Xinjiang Medical University. First Affiliated Hospital of Shihezi University.China International ImmunopharmacologyInt Immunopharmacol 2026; DOI: 10.1016/j.intimp.2026.116712 AbstractPulmonary arterial hypertension (PAH) is a debilitating and fatal cardiovascular disorder marked by

Inflachromene attenuates monocrotaline-induced pulmonary arterial hypertension by suppressing the HMGB1-TLR4/RAGE-NF-κB signaling pathway Read More »

R213G-Mediated Redistribution of EC-SOD Protects Against Sugen-Hypoxia Pulmonary Hypertension in Mice

Daniel Colon Hidalgo, Caitlin V. Lewis, Thi‐Tina N. Nguyen, Janelle N. Posey, Samuel D. Burciaga, Nathan Dee, Christina Sul, Julie Harral, David Irwin, Cassidy Delaney, Eva S. NozikUniversity of Colorado Anschutz Medical Campus. United States Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70307 AbstractPulmonary hypertension (PH) is a progressive and life-threatening disease characterized by pulmonary vascular remodeling

R213G-Mediated Redistribution of EC-SOD Protects Against Sugen-Hypoxia Pulmonary Hypertension in Mice Read More »

Scroll to Top